Browsing by Author "Peruničić, Jovan (9738988200)"

Patients with EuroSCORE <2 are usually considered to have a low surgical risk and the lowest mortality. In our study preoperative factors in a group of 250 consecutive low-risk patients (EuroSCORE<2), who underwent frst isolated coronary artery by-pass surgery during 1999 and 2000., were analyzed. Cumulative follow-up period was 1178.48 patient-years and the primary clinical outcome was all-cause mortality. Patients̀ average age was 59.2±7.5 yr. The following preoperative risk factors of increased 5-year mortality were identifed: older age (P<0.001), smoking, prior non-recent myocardial infarction and reinfarction, anteroseptal localization of myocardial infarction (P<0.001), poor ejection fraction<=35% (P<0.001), dilatative cardiomyopathy (P<0.001), wall motion systolic index >2 (P<0.001), left atrial dilatation (P<0.001), mitral regurgitation more than 2+ (P<0.001), presence of left main disease, triple vessel coronary artery disease (P<0.001), absence of collaterals (P<0.001) and presence of more than 3 distal anastomoses. Through the present study it has been shown that it is possible to identify a subgroup of patients with low operative mortality and excellent 5-year survival after surgical treatment for coronary artery bypass surgery using preoperative clinical, echocardiographic, coronarographic and intraoperative data, even in diffcult conditions of the civil war in the region. © Versita Sp. z o.o.

Hyperhomocysteinemia (HHcy) is considered one of the factors related to premature atherothrombosis. Study compares incidences of HHcy, defined as homocysteinemia above 12 μmol/L, and medians of homocysteinemia between the groups of 212 patients with acute myocardial infarction (AMI) younger than 45 years of age and 45 age-matched healthy persons. Homocysteine was determined by a HPLC method with fluorescent detection. Results were compared by chi-square, Mann-Whitney U and Kruskal-Wallis tests. Significant difference (p=0.001) was observed between incidence of HHcy in patients (44.8%) and incidence in controls (17.8%). Medians of homocysteinemia levels in patients (11.4 μmol/L) and controls (9.7 μmol/L) were significantly different (p=0.001). Gender-specific differences in incidence of HHcy and in median homocysteinemia value in patients were not significant. Incidences of HHcy in female patients (47.1%) and in healthy women (4.8%) were significantly different (p=0.001). Comparison of median homocysteinemia levels in women with AMI (10.9 μmol/L) and in female controls (9.0 μmol/L) revealed significant difference (p=0.025). Such differences were not observed in male subjects of our study. No significant difference was found when incidences of HHcy and medians of homocysteinemia were compared between defined age groups of patients. We conclude that young patients with AMI have higher incidence of hyperhomocysteinemia and higher level of homocysteinemia than healthy persons. Young women with AMI have higher incidence of hyperhomocysteinemia and higher level of homocysteine than healthy young women.

Hyperhomocysteinemia (HHcy) is considered one of the factors related to premature atherothrombosis. Study compares incidences of HHcy, defined as homocysteinemia above 12 μmol/L, and medians of homocysteinemia between the groups of 212 patients with acute myocardial infarction (AMI) younger than 45 years of age and 45 age-matched healthy persons. Homocysteine was determined by a HPLC method with fluorescent detection. Results were compared by chi-square, Mann-Whitney U and Kruskal-Wallis tests. Significant difference (p=0.001) was observed between incidence of HHcy in patients (44.8%) and incidence in controls (17.8%). Medians of homocysteinemia levels in patients (11.4 μmol/L) and controls (9.7 μmol/L) were significantly different (p=0.001). Gender-specific differences in incidence of HHcy and in median homocysteinemia value in patients were not significant. Incidences of HHcy in female patients (47.1%) and in healthy women (4.8%) were significantly different (p=0.001). Comparison of median homocysteinemia levels in women with AMI (10.9 μmol/L) and in female controls (9.0 μmol/L) revealed significant difference (p=0.025). Such differences were not observed in male subjects of our study. No significant difference was found when incidences of HHcy and medians of homocysteinemia were compared between defined age groups of patients. We conclude that young patients with AMI have higher incidence of hyperhomocysteinemia and higher level of homocysteinemia than healthy persons. Young women with AMI have higher incidence of hyperhomocysteinemia and higher level of homocysteine than healthy young women.

Hyperhomocysteinemia is considered an independent risk factor for premature cardiovascular disease. Mutation MTHFR C677T reduces the activity of methylenetetra-hydrofolatereductase and may cause hyperhomocysteinemia. Incidence of hyperhomocysteinemia (homocysteine above 12 μmol/L), homocysteine level, and distribution of MTHFR C677T genotypes (C/C, C/T and T/T) are compared between young patients with acute myocardial infarction and healthy persons, matched by age. Study involved 86 patients younger than 45 years (77 men and 9 women) and 35 controls. Homocysteine was measured by an HPLC method and the MTHFR C677T genotype determined using PCR amplification and digestion with Hinf I. Statistical analyses included chisquare and Mann-Whitney U tests. Hyperhomocysteinemia was present in 32.6% patients and 14.3% controls, revealing a significant difference (P= 0.038). Median homocysteine levels in patients (10.4 μmol/L) and controls (9.6 μmol/L) were significantly different (P=0.035). Among patients, 50.0% had C/C, 41.9% C/T and 8.1% T/T genotype, and the genotype had no influence on hyperhomocysteinemia incidence and homocysteine level. Genotype distribution in patients was not significantly different from that observed in controls. The conclusion is that young patients with acute myocardial infarction have higher incidence of hyperhomocysteinemia and higher homocysteine levels than healthy young adults, while there is no significant difference in the distribution of MTHFR C677T genotypes.

Hyperhomocysteinemia is considered an independent risk factor for premature cardiovascular disease. Mutation MTHFR C677T reduces the activity of methylenetetra-hydrofolatereductase and may cause hyperhomocysteinemia. Incidence of hyperhomocysteinemia (homocysteine above 12 μmol/L), homocysteine level, and distribution of MTHFR C677T genotypes (C/C, C/T and T/T) are compared between young patients with acute myocardial infarction and healthy persons, matched by age. Study involved 86 patients younger than 45 years (77 men and 9 women) and 35 controls. Homocysteine was measured by an HPLC method and the MTHFR C677T genotype determined using PCR amplification and digestion with Hinf I. Statistical analyses included chisquare and Mann-Whitney U tests. Hyperhomocysteinemia was present in 32.6% patients and 14.3% controls, revealing a significant difference (P= 0.038). Median homocysteine levels in patients (10.4 μmol/L) and controls (9.6 μmol/L) were significantly different (P=0.035). Among patients, 50.0% had C/C, 41.9% C/T and 8.1% T/T genotype, and the genotype had no influence on hyperhomocysteinemia incidence and homocysteine level. Genotype distribution in patients was not significantly different from that observed in controls. The conclusion is that young patients with acute myocardial infarction have higher incidence of hyperhomocysteinemia and higher homocysteine levels than healthy young adults, while there is no significant difference in the distribution of MTHFR C677T genotypes.